Loading cancer entity…
Loading cancer entity…
Clinical trials
8,120 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,290)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00553644 | Bortezomib and Lenalidomide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma | completed | Phase 2 | 53 | National Cancer Institute (NCI)NIH | 1 | Oct 30, 2018 | clinicaltrials |
| NCT00038376 | Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies | completed | Phase 2 | 56 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 29, 2018 | clinicaltrials |
| NCT00896454 | Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium | completed | Phase 2 | 33 | AmgenINDUSTRY | 5 | Oct 17, 2018 | clinicaltrials |
| NCT03000452 | A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)(FUSION-MM-005) | completed | Phase 2 | 18 | CelgeneINDUSTRY | 6 | Oct 16, 2018 | clinicaltrials |
| NCT02669615 | Pharmacokinetic Study of Propylene Glycol-Free Melphalan HCl for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation | completed | Phase 2 | 24 | Medical College of WisconsinOTHER | 1 | Oct 10, 2018 | clinicaltrials |
| NCT00976248 | Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia | completed | Phase 2 | 33 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 3, 2018 | clinicaltrials |
| NCT01693614 | Safety and Efficacy of BKM120 in Relapsed and Refractory NHL | completed | Phase 2 | 72 | Novartis PharmaceuticalsINDUSTRY | 8 | Sep 28, 2018 | clinicaltrials |
| NCT00001873 | The Role of Cyclosporine in Blood Cell Transplants With T-Cell Add-Back for Blood Cancers | completed | Phase 2 | 102 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Sep 26, 2018 | clinicaltrials |
| NCT00024466 | Chemotherapy, Vaccine Therapy, and Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 1 / Phase 2 | 28 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 19, 2018 | clinicaltrials |
| NCT01848132 | Efficacy/Safety Study of R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lymphoma With Poor IPI. | completed | Phase 2 | 121 | Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaOTHER | 1 | Sep 19, 2018 | clinicaltrials |
| NCT01024010 | Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 2 | 82 | Mayo ClinicOTHER | 1 | Sep 18, 2018 | clinicaltrials |
| NCT01355705 | Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 14 | Michaela LiedtkeOTHER | 1 | Sep 18, 2018 | clinicaltrials |
| NCT01910025 | PH 2 ADI-PEG 20 Study in Non-Hodgkin's Lymphoma Subjects Who Have Failed Prior Systemic Therapy | completed | Phase 2 | 18 | Polaris GroupINDUSTRY | 1 | Sep 18, 2018 | clinicaltrials |
| NCT01706666 | Bortezomib Based Consolidation in Multiple Myeloma Patients Completing Stem Cell Transplant | completed | Phase 2 | 3 | Mayo ClinicOTHER | 1 | Sep 17, 2018 | clinicaltrials |
| NCT01273766 | Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies | completed | Phase 2 | 16 | Wake Forest University Health SciencesOTHER | 1 | Sep 7, 2018 | clinicaltrials |
| NCT02280785 | Brentuximab Vedotin for Relapsed/Refractory CD30-positive Non-Hodgkin Lymphomas(BRAN) | completed | Phase 2 | 33 | Samsung Medical CenterOTHER | 1 | Sep 6, 2018 | clinicaltrials |
| NCT02424045 | Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-cell Lymphoma | completed | Phase 2 | 30 | Samsung Medical CenterOTHER | 0 | Sep 6, 2018 | clinicaltrials |
| NCT01272466 | Vaccination With Peptides From Anti-apoptotic Proteins in Relapsed Multiple Myeloma | completed | Phase 1 / Phase 2 | 40 | Herlev HospitalOTHER | 1 | Aug 31, 2018 | clinicaltrials |
| NCT01686165 | Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL | completed | Phase 2 | 5 | University of ArizonaOTHER | 1 | Aug 28, 2018 | clinicaltrials |
| NCT01707264 | Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis | completed | Phase 1 / Phase 2 | 69 | Prothena Biosciences Ltd.INDUSTRY | 1 | Aug 28, 2018 | clinicaltrials |
| NCT00136565 | Study of Bortezomib Combined With ACVBP in Peripheral T-cell Lymphoma | completed | Phase 2 | 60 | Lymphoma Study AssociationOTHER | 2 | Aug 23, 2018 | clinicaltrials |
| NCT00901615 | Lenalidomide and R-CHOP in B-cell Lymphoma(R2CHOP-1) | completed | Phase 1 / Phase 2 | 108 | Lymphoma Study AssociationOTHER | 1 | Aug 23, 2018 | clinicaltrials |
| NCT00535873 | Lenalidomide as Initial Treatment of Patients With Chronic Lymphocytic Leukemia (CLL) Age 65 and Older | completed | Phase 2 | 61 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 21, 2018 | clinicaltrials |
| NCT01794039 | Pomalidomide or Lenalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Previously Treated With Lenalidomide | completed | Phase 2 | 9 | Mayo ClinicOTHER | 1 | Aug 21, 2018 | clinicaltrials |
| NCT01852799 | A Study of PAD Followed by Autologous Stem Cell Transplantation (ASCT) to Treat Newly Diagnosed Multiple Myeloma | completed | Phase 2 | 18 | Shanghai Changzheng HospitalOTHER | 1 | Aug 10, 2018 | clinicaltrials |
| NCT00064337 | S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis | completed | Phase 2 | 104 | SWOG Cancer Research NetworkNETWORK | 1 | Aug 9, 2018 | clinicaltrials |
| NCT01294579 | Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL) | completed | Phase 2 | 49 | Novartis PharmaceuticalsINDUSTRY | 1 | Aug 9, 2018 | clinicaltrials |
| NCT00703664 | Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma | completed | Phase 2 | 65 | National Cancer Institute (NCI)NIH | 1 | Aug 7, 2018 | clinicaltrials |
| NCT01690143 | Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation | completed | Phase 1 / Phase 2 | 45 | University of Alabama at BirminghamOTHER | 1 | Aug 7, 2018 | clinicaltrials |
| NCT02206503 | Cyclophosphamide With Biochemical Progression During Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma (MM) | completed | Phase 2 | 13 | Fondazione EMN Italy OnlusOTHER | 1 | Aug 2, 2018 | clinicaltrials |
| NCT02331368 | Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma | completed | Phase 2 | 32 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jul 27, 2018 | clinicaltrials |
| NCT01789255 | Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies | completed | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Jul 24, 2018 | clinicaltrials |
| NCT01610180 | Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs) | completed | Phase 2 | 18 | Fondazione Progetto EmatologiaOTHER | 1 | Jul 16, 2018 | clinicaltrials |
| NCT01526694 | Phase II Trial Designed to Determine Efficacy and Safety of Bendamustine+Dexamethasone+Thalidomide in R/R MM | completed | Phase 2 | 30 | Azienda Ospedaliera di BolzanoOTHER | 1 | Jul 3, 2018 | clinicaltrials |
| NCT00119392 | Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | completed | Phase 2 | 42 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 29, 2018 | clinicaltrials |
| NCT00151281 | Phase II Study of RT-PEPC in Relapsed Mantle Cell Lymphoma | completed | Phase 2 | 25 | Weill Medical College of Cornell UniversityOTHER | 1 | Jun 28, 2018 | clinicaltrials |
| NCT00336583 | Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin as 2nd Line Therapy for Non-Hodgkin's Lymphoma (NHL) | completed | Phase 2 | 27 | Asan Medical CenterOTHER | 1 | Jun 26, 2018 | clinicaltrials |
| NCT01563302 | Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers | completed | Phase 1 / Phase 2 | 64 | Ionis Pharmaceuticals, Inc.INDUSTRY | 1 | Jun 25, 2018 | clinicaltrials |
| NCT01985126 | An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD | completed | Phase 2 | 124 | Janssen Research & Development, LLCINDUSTRY | 3 | Jun 25, 2018 | clinicaltrials |
| NCT00151320 | Phase I/II Trial of VELCADE + CHOP-Rituximab in Untreated DLCBL or Mantle Cell NHL | completed | Phase 1 / Phase 2 | 76 | Weill Medical College of Cornell UniversityOTHER | 1 | Jun 19, 2018 | clinicaltrials |
| NCT01724177 | A Phase 2 Study of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma | completed | Phase 2 | 26 | CelgeneINDUSTRY | 1 | May 29, 2018 | clinicaltrials |
| NCT00961220 | O6-Benzylguanine and Topical Carmustine in Treating Patients With Early-Stage IA-IIA Cutaneous T-Cell Lymphoma | completed | Phase 1 / Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | May 22, 2018 | clinicaltrials |
| NCT01478048 | Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 185 | Bristol-Myers SquibbINDUSTRY | 5 | May 21, 2018 | clinicaltrials |
| NCT00669877 | Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma | completed | Phase 2 | 56 | M.D. Anderson Cancer CenterOTHER | 1 | May 16, 2018 | clinicaltrials |
| NCT01215344 | First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade | completed | Phase 2 | 36 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | May 15, 2018 | clinicaltrials |
| NCT00884312 | A Study of Extended Carfilzomib Therapy for Patients Previously Enrolled in Carfilzomib Treatment Protocols | completed | Phase 2 | 101 | AmgenINDUSTRY | 2 | May 14, 2018 | clinicaltrials |
| NCT00539695 | Low Dose IL-2, Hematopoietic Stem Cell Transplantation, IL2 for GVHD(IL2 for GVHD) | completed | Phase 2 | 25 | Baylor College of MedicineOTHER | 1 | May 4, 2018 | clinicaltrials |
| NCT00574288 | Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma | completed | Phase 2 | 104 | Janssen Research & Development, LLCINDUSTRY | 4 | Apr 27, 2018 | clinicaltrials |
| NCT01030536 | Safety Study of CAT-8015 to Treat Advanced B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (NHL or CLL) | completed | Phase 1 / Phase 2 | 23 | MedImmune LLCINDUSTRY | 2 | Apr 9, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Oct 30, 2018source: clinicaltrials